Literature DB >> 15652389

Knock down of the alpha 5 nicotinic acetylcholine receptor in spinal nerve-ligated rats alleviates mechanical allodynia.

Michelle A Vincler1, James C Eisenach.   

Abstract

Nicotinic acetylcholine receptor (nAChR) agonists are known to alleviate neuropathic and inflammatory pain via activation of a heterogeneous population of receptors. However, the function of nAChRs in the maintenance of neuropathic pain is not known. Spinal nerve ligation (SNL) increases the spinal expression of the alpha5 nAChR subunit ipsilateral to injury. The alpha5 subunit is unique because it modifies numerous characteristics of existing functional nAChRs, but it does not form functional nAChRs when expressed alone or with beta nicotinic subunits. Because there are no alpha5 subunit selective ligands, we used antisense oligonucleotides (ODNs) to assess the contribution of the alpha5 subunit to the maintenance of mechanical allodynia following SNL. Intrathecal antisense oligonucleotides were administered to SNL rats after the development of mechanical allodynia (10-12 days post-SNL). I.t. antisense specifically reduced alpha5 immunoreactivity (alpha5-IR) by 50-70% in the outer laminae of the dorsal horn and moderately alleviated mechanical allodynia. Furthermore, using the phosphorylation of cAMP response element-binding protein (pCREB) as a general marker of neuronal activation, a significant increase in pCREB immunoreactivity was observed in SNL rats. Treatment of SNL rats with alpha5-antisense significantly reduced pCREB immunoreactivity. These results suggest that the increased expression of the alpha5 nAChR subunit following SNL contributes to spinal CREB phosphorylation and the maintenance of mechanical allodynia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15652389     DOI: 10.1016/j.pbb.2004.10.011

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  13 in total

1.  The role of alpha5 nicotinic acetylcholine receptors in mouse models of chronic inflammatory and neuropathic pain.

Authors:  Deniz Bagdas; Shakir D AlSharari; Kelen Freitas; Matthew Tracy; M Imad Damaj
Journal:  Biochem Pharmacol       Date:  2015-04-28       Impact factor: 5.858

2.  Impact of chronic nicotine on the development and maintenance of neuropathic hypersensitivity in the rat.

Authors:  Darnell T Josiah; Michelle A Vincler
Journal:  Psychopharmacology (Berl)       Date:  2006-08-17       Impact factor: 4.530

3.  Role of α5* nicotinic acetylcholine receptors in the effects of acute and chronic nicotine treatment on brain reward function in mice.

Authors:  Christie D Fowler; Luis Tuesta; Paul J Kenny
Journal:  Psychopharmacology (Berl)       Date:  2013-08-20       Impact factor: 4.530

4.  Antinociceptive and anti-inflammatory effects of choline in a mouse model of postoperative pain.

Authors:  T J Rowley; A McKinstry; E Greenidge; W Smith; P Flood
Journal:  Br J Anaesth       Date:  2010-05-28       Impact factor: 9.166

5.  Low concentrations of amitriptyline inhibit nicotinic receptors in unmyelinated axons of human peripheral nerve.

Authors:  A Freysoldt; J Fleckenstein; P M Lang; D Irnich; P Grafe; R W Carr
Journal:  Br J Pharmacol       Date:  2009-08-19       Impact factor: 8.739

6.  Modulation of the Ca2+ conductance of nicotinic acetylcholine receptors by Lypd6.

Authors:  Martin Darvas; Marco Morsch; Ildiko Racz; Seifollah Ahmadi; Dieter Swandulla; Andreas Zimmer
Journal:  Eur Neuropsychopharmacol       Date:  2009-04-29       Impact factor: 4.600

7.  Peripheral nerve injury alters spinal nicotinic acetylcholine receptor pharmacology.

Authors:  Tracey Young; Shannon Wittenauer; Renee Parker; Michelle Vincler
Journal:  Eur J Pharmacol       Date:  2008-06-11       Impact factor: 4.432

Review 8.  Neuronal nicotinic receptors as analgesic targets: it's a winding road.

Authors:  Iboro C Umana; Claire A Daniele; Daniel S McGehee
Journal:  Biochem Pharmacol       Date:  2013-08-12       Impact factor: 5.858

9.  Alpha7 cholinergic-agonist prevents systemic inflammation and improves survival during resuscitation.

Authors:  Bolin Cai; Fei Chen; Yan Ji; Levente Kiss; Wouter J de Jonge; Concepcion Conejero-Goldberg; Csaba Szabo; Edwin A Deitch; Luis Ulloa
Journal:  J Cell Mol Med       Date:  2008-10-17       Impact factor: 5.310

10.  Stem cell therapy for neuropathic pain treatment.

Authors:  D Siniscalco; F Rossi; S Maione
Journal:  J Stem Cells Regen Med       Date:  2007-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.